IRVINE, Calif., June 25, 2013 /PRNewswire/ -- High Performance Nutrition (HPN) today announced the launch of N(R)TM, an innovative daily nutritional supplement designed to protect against axon degeneration damage or trauma sustained in the course of playing contact sports. N(R) is one of the first commercially available products to feature the ingredient NIAGENTM from ChromaDex Corporation® (OTCBB: CDXC), an innovative natural products company that provides proprietary, science-based solutions and ingredients to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries.
ChromaDex Inc. developed its breakthrough ingredient NIAGEN as the patent-protected and first and only commercially available brand of nicotinamide riboside, which is known to boost levels of NAD+ in the cells. Studies have demonstrated that increasing the production of NAD+ can protect against axon degeneration caused by mechanical or neurological injury.
Recent studies have demonstrated that the head trauma that occurs in contact sports can lead to brain damage. The prevalence of repeated blows to the head in contact sports such as football, soccer and hockey has raised the concern of scientists, public officials, athletes and parents. Sean Torbati, CEO and president of HPN, believes in the importance and responsibility of protecting the health of athletes, especially that of America's youth, from debilitating brain injuries. His company has tapped into NIAGEN as a protective measure with the introduction of N(R)TM.
"N(R) addresses the recent discovery that protection from brain injury should start off the field before it continues on the field with barriers such as helmets," said Torbati. "About three million children younger than 14 play organized tackle football in the United States, not to mention the millions playing competitively in high school, college and beyond, as well as the millions more engaging in other sports in which helmets are worn such as baseball, lacrosse, hockey or even horseback riding. Recent findings that athletes playing soccer are also at risk for brain injury further demonstrates the potential for N(R) to be used by athletes worldwide."
Frank Jaksch, founder and CEO of ChromaDex, states "HPN is forging into a new and innovative market with N(R) by aiming to prevent or delay axonal degeneration before trauma even occurs. Backed by scientific evidence and patented nutrition technology [US7776326], N(R) is poised to revolutionize how players of contact sports think about potentially protecting themselves in the long run."
Sean Torbati further comments, "An asset as important as the human brain deserves the most protection possible, not just when you step onto the field and put on that helmet. It's a no-brainer."
For more information, please visit http://hpnformula1.com/store/Nr/
About Nicotinamide Riboside (NR):
Sometimes referred to as the "Miracle Molecule" or the "Hidden Vitamin," NR is found naturally in trace amounts in milk and other foods and is a more potent, no-flush version of Niacin (vitamin B3). The beneficial effects of NR in humans include increased fatty acid oxidation, mitochondrial activity, resistance to the negative consequences of high-fat diets, protection against oxidative stress, prevention of peripheral neuropathy and the blocking muscle degeneration.
Published research has shown that NR is perhaps the most potent precursor to NAD+ in the mitochondria of animals. NAD+ is arguably the most important cellular co-factor for improvement of mitochondrial performance and energy metabolism. Mitochondria also play an important part in the aging process. It is hoped that by stimulating mitochondrial function with the NR molecule, scientists may see increased longevity as well as other health improvements. Researchers worldwide continue their seminal discoveries in providing evidence for unique properties of NR in neuroprotection, sirtuin activation, protection against weight gain on high fat diets and improvement of blood glucose and insulin sensitivity.
HPN LLC was founded in 2010 with its mission being to set a new standard for quality, safety, innovation and effectiveness in the natural sports nutrition industry. The "no compromises" approach to every aspect of HPN's product development, manufacturing and testing sets the company apart from the rest of the sports nutrition category.
ChromaDex® is an innovative natural products company that discovers, acquires, develops and commercializes proprietary-based ingredient technologies through its unique business model which utilizes its wholly owned synergistic business units, including ingredient technologies, natural product fine chemicals (known as "phytochemicals"), chemistry and analytical testing services and product regulatory and safety consulting (as Spherix Consulting). The company provides seamless science-based solutions to the dietary supplement, food and beverage, animal health, cosmetic and pharmaceutical industries. Our ingredient technologies unit includes products backed with extensive scientific research and intellectual property. The ingredient portfolio includes pTeroPure®; pterostilbene; ProC3G™, a natural black rice containing cyanidine-3-glucoside; PURENERGY™, a caffeine-pTeroPure co-crystal; nutraGac™, a gac fruit powder; curcumin; and NIAGEN™, its recently launched branded nicotinamide riboside, a novel next-generation B-vitamin. To learn more about ChromaDex please visit www.chromadex.com.
Any statements that are not historical facts contained in this release are forward-looking statements. Actual results may differ materially from those projected or implied in any forward-looking statements. Such statements involve risks and uncertainties, including but not limited to those relating to product and customer demand, market acceptance of our products, the effect of economic conditions both nationally and internationally, ability to protect our intellectual property rights, impact of any litigation or infringement actions brought against us, competition from other providers and products, risks in product development, our ability to raise capital to fund continuing operations, the ability to complete transactions, and other factors discussed from time to time in the company's Securities and Exchange Commission filings. The company undertakes no obligation to update or revise any forward-looking statement for events or circumstances after the date on which such statement is made except as required by law.
ChromaDex Investor Contact:
The Del Mar Consulting Group, Inc.
Robert B. Prag, President
Alex Partners, LLC
Scott Wilfong, President
Laura Carney, Executive Assistant
These statements in this press release have not been evaluated by the Food and Drug Administration. Products or ingredients are not intended to diagnose, treat, cure or prevent any disease.